Search Result
Results for "
thromboxanes
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
5
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-120980
-
TXB1
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Thromboxane B1 (TXB1) is one of thromboxane B (TXB) family members. Thromboxane is a member of the family of lipids known as eicosanoids. Thromboxane is named for its role in blood clot formation (thrombosis) .
|
-
-
- HY-124353
-
11-Dehydro-TXB3
|
Endogenous Metabolite
|
Others
|
11-Dehydro thromboxane B3 (11-Dehydro-TXB3) is a urinary metabolite of Thromboxane A3 (TXA3) .
|
-
-
- HY-105114
-
|
Others
|
Inflammation/Immunology
|
Imitrodast is an inhibitor of thromboxane synthase. Imitrodast can be used in the research of bronchoconstriction .
|
-
-
- HY-10419A
-
-
-
- HY-129614
-
-
-
- HY-116281
-
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
ICI D1542 is a selective and potent inhibitor of thromboxane A2 (TXA2) synthase and the thromboxane A2 receptor (TP-receptor). ICI D1542 is effective at preventing thrombus formation by redirection of arachidonic acid metabolism .
|
-
-
- HY-A0221
-
R 68070
|
Prostaglandin Receptor
|
Inflammation/Immunology
|
Ridogrel (R 68070) is an orally active combined thromboxane A2 synthetase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor blocker. Ridogrel is potent antiplatelet agent. Anti-inflammatory activities .
|
-
-
- HY-136500
-
PGH2
|
Endogenous Metabolite
|
Cardiovascular Disease
|
Prostaglandin H2 (PGH2), a potent vasoconstrictor, is produced by the conversion of Arachidonic acid (AA). Prostaglandin H2 is asubstrate for the production of Prostaglandins (PGs) and thromboxanes (TXs) .
|
-
-
- HY-108972
-
-
-
- HY-120178
-
|
Others
|
Cardiovascular Disease
|
(±)7(8)-DiHDPA is a epoxygenase metabolite of docosahexaenoic acid (HY-B2167). (±)7(8)-DiHDPA inhibits platelet aggregation at concentrations below those affecting thromboxane synthesis .
|
-
-
- HY-120442
-
|
Others
|
Cardiovascular Disease
|
(±)16(17)-DiHDPA is a epoxygenase metabolite of docosahexaenoic acid (HY-B2167). (±)16(17)-DiHDPA inhibits platelet aggregation at concentrations below those affecting thromboxane synthesis .
|
-
-
- HY-160664
-
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
TP receptor antagonist-2 (example 7n) is a thromboxane A2 receptor (TP receptor) antagonist, with IC50 values of 5.64 and 5.27 μM for TPα and TPβ, respectively. TP receptor antagonist-2 inhibits platelet aggregation .
|
-
-
- HY-B0428A
-
OKY-046 sodium
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Ozagrel sodium (OKY-046 sodium) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel sodium is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC50 of 53.12 μM .
|
-
-
- HY-B0428B
-
OKY-046 hydrochloride
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Ozagrel hydrochloride (OKY-046 hydrochloride) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel hydrochloride is an antiplatelet agent, which selectively inhibits human platelet aggregationwith an IC50 of 53.12 μM .
|
-
-
- HY-B0428
-
Ozagrel
1 Publications Verification
OKY-046
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Ozagrel (OKY-046)is an anti-asthmatic agent and a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC50 of 53.12 μM .
|
-
-
- HY-B0428BR
-
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Ozagrel (hydrochloride) (Standard) is the analytical standard of Ozagrel (hydrochloride). This product is intended for research and analytical applications. Ozagrel hydrochloride (OKY-046 hydrochloride) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel hydrochloride is an antiplatelet agent, which selectively inhibits human platelet aggregationwith an IC50 of 53.12 μM .
|
-
-
- HY-129496
-
|
Thrombin
|
Cardiovascular Disease
|
NP-313 is a potent antithrombotic agent that inhibits platelet aggregation and activation. NP-313 has dual inhibition of thromboxane A 2 synthesis and selective inhibition of SOCC-mediated Ca 2+ inward flow .
|
-
-
- HY-W273690
-
1-Hexyltheobromine; Hexyltheobromine
|
Others
|
Cardiovascular Disease
|
Pentifylline is a vasodilator. Pentifylline inhibits platelet aggregation and thromboxane A2 synthesis, decrease the release of free radicals. Pentifylline has the potential for the research of acute ischaemic stroke .
|
-
-
- HY-129851
-
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
NTP42 is a thromboxane A2 (TXA2) receptor antagonist with an IC50 of 3.278 nM for antagonizing T prostanoid receptor (TP)- mediated [Ca 2+] mobilization following stimulation of cells with the alternative TP agonist U46619 . NTP42 can be used for the treatment of pulmonary arterial hypertension (PAH) .
|
-
-
- HY-105120A
-
GR 32191 hydrochloride
|
Prostaglandin Receptor
|
Others
|
Vapiprost hydrochloride (GR 32191 hydrochloride) is a thromboxane A2 receptor antagonist. Vapiprost hydrochloride (GR 32191 hydrochloride) inhibits the aggregation and ATP release stimulated with U-46619, collagen or arachidonic acid (AA) at an IC50 of less than 2.1×10 -8 M .
|
-
-
- HY-114846
-
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Ro 22-9194 inhibits aggregation and thromboxane Az (TXA2) synthetase activity in rabbit and human platelets. Ro 22-9194 has a potent inhibitory action against various types of model arrhythmias. Ro 22-9194 has non-cholinergic cardiac depressant properties with its vasodilating action .
|
-
-
- HY-130304
-
iPE2-III
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
8-Isoprostaglandin E2 (iPE2-III) is a member of the isoprostane class of prostanoids. 8-Isoprostaglandin E2 acts at the receptor for thromboxane A2 (the TP) in vivo to induce vasoconstriction and platelet aggregation. 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway .
|
-
-
- HY-106961
-
ONO-AP 500-02
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig .
|
-
-
- HY-113331S
-
|
Isotope-Labeled Compounds
|
Inflammation/Immunology
|
Thromboxane B2-D4 is the deuterium labeled Thromboxane B2. Thromboxane B2 is a prostaglandin derivative that is released during anaphylaxis. Thromboxane B2 induces arterial contraction and platelet aggregation .
|
-
-
- HY-113420S2
-
|
Endogenous Metabolite
Isotope-Labeled Compounds
|
Metabolic Disease
|
11-Dehydro-thromboxane B2- 13C5 is 13C labeled 11-Dehydro-thromboxane B2 (HY-113420). 11-Dehydro-thromboxane B2 is a platelet hemagglutinin. Thromboxane inhibition was assessed by urinary excretion levels of 11-Dehydro-thromboxane B2. 11-Dehydro-thromboxane B2 can be used in the study of atherosclerotic thrombosis .
|
-
-
- HY-113350
-
TXA2
|
Prostaglandin Receptor
Endogenous Metabolite
|
Inflammation/Immunology
Endocrinology
Cancer
|
Thromboxane A2 (TXA2) is a prostanoid mediator produced by the metabolism of Arachidonic acid (HY-109590) through the cyclooxygenase pathway. Thromboxane A2 activates the thromboxane-prostanoid (TP) receptors. Thromboxane A2 is a potent vasoconstrictor eicosanoid. Thromboxane A2 (TXA2) leads to potent vasoconstriction by stimulation of smooth muscle cells. Thromboxane A2 acts as s tonic immunoregulator to regulate adaptive immune responses .
|
-
-
- HY-113420
-
|
Endogenous Metabolite
|
Metabolic Disease
|
11-Dehydro-thromboxane B2 is a platelet hemagglutinin. Thromboxane inhibition was assessed by urinary excretion levels of 11-Dehydro-thromboxane B2. 11-Dehydro-thromboxane B2 can be used in the study of atherosclerotic thrombosis .
|
-
-
- HY-160615
-
-
-
- HY-N0652
-
2,3,4',5-Tetrahydroxystilbene 2-O-D-glucoside
|
ERK
NF-κB
|
Cardiovascular Disease
Neurological Disease
|
2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside isolats from the roots of Polygonaceae species, inhibits the formation of 5-HETE, HHT and thromboxane B2. 2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside has hypotensive, anti-ageing, anti-inflammatory, hypolipidemic, cardioprotective, and neuroprotective actions .
|
-
-
- HY-106961A
-
(Z)-ONO-AP 500-02
|
Others
|
Cardiovascular Disease
|
(Z)-ONO 1301 is the isomer of ONO 1301 (HY-106961), and can be used as an experimental control. ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig .
|
-
-
- HY-113331
-
|
Others
|
Inflammation/Immunology
|
Thromboxane B2 is a prostaglandin derivative that is released during anaphylaxis. Thromboxane B2 induces arterial contraction and platelet aggregation.
|
-
-
- HY-113445
-
|
COX
Endogenous Metabolite
|
Endocrinology
|
Thromboxane B3 is a prostaglandin analog derived from arachidonic acid (AA) in the cyclooxygenase (COX) metabolic pathway. Thromboxane B3 is generated from arachidonic acid (AA) in platelets and vascular endothelial cells through the catalysis of cyclooxygenase (COX) and thromboxane synthase (TXS). Thromboxane B3 has been reported to be formed by human platelets upon ingestion of eicosapentaenoic acid (C20: 5ω3) .
|
-
-
- HY-19189
-
-
-
- HY-126923
-
2,3-Dinor-TXB2
|
Others
|
Cardiovascular Disease
Metabolic Disease
|
2,3-Dinor thromboxane B2 (2,3-Dinor-TXB2), a metabolite of urine, serves as an indicator of the production of thromboxane A2 (TxA2) in the body, and can be used as a tool to study the role of thromboxane in various pathophysiological processes in the human body .
|
-
-
- HY-U00072
-
-
-
- HY-113420S
-
-
-
- HY-16991
-
-
-
- HY-101692
-
-
-
- HY-124150
-
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
BM567 is a sulfonylurea compound (compound 1), which exhibits antithrombogenic efficacy as thromboxane A2 receptor (TXR) antagonists and thromboxane A2 synthase (TXS) inhibitors, with IC50s of 1.1 and 12 nM, respectively .
|
-
-
- HY-106067A
-
-
-
- HY-106080A
-
U-63557A
|
Others
|
Cardiovascular Disease
|
Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .
|
-
-
- HY-106080
-
U-63557A free acid
|
Others
|
Cardiovascular Disease
|
Furegrelate (U-63557A free acid) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate is being developed as an antiplatelet agent .
|
-
-
- HY-158332
-
SKF-95587; BM-13177
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Sulotroban (SKF-95587; BM-13177) is a selective antagonist for thromboxane A2 receptor (TXA2 Receptor). Sulotroban exhibits inhibitory activity against carbocyclic thromboxane A2- and endoperoxide-induced vasoconstrictor. Sulotroban inhibits platelets aggregation .
|
-
-
- HY-114564
-
E5510
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Satigrel (E5510) is a potent inhibitor of platelet aggregation. Satigrel inhibits collagen- and arachidonic acid-induced platelet aggregation through preventing thromboxane A2 synthesis by selective inhibition of the target enzyme, PGHS1, which exists in platelets. Satigrel inhibits PGHS1 (IC50: 0.081 μM) and PGHS2 (IC50: 5.9 μM). Satigrel is against Type III PDE, Type V and Type II (IC50: 15.7 μM, 39.8 μM and 62.4 μM, respectively) .
|
-
-
- HY-101606
-
-
-
- HY-101700
-
-
-
- HY-B0531
-
|
COX
|
Inflammation/Immunology
|
Triflusal irreversibly inhibits the production of thromboxane-B2 in platelets by acetylating cycloxygenase-1.
|
-
-
- HY-U00253
-
-
-
- HY-106119
-
|
Prostaglandin Receptor
|
Infection
|
Camonagrel is a compound that has inhibitory effects on Prostaglandin E2. Camonagrel is a potent thromboxane synthase inhibitor .
|
-
-
- HY-109877
-
4'-(Imidazol-1-yl) acetophenone
|
Others
|
Cardiovascular Disease
|
Ro 22-3581 (4'-(Imidazol-1-yl) acetophenone) is a selective thromboxane (Tx) synthetase inhibitor .
|
-
- HY-130444
-
Pinane-thromboxanea2synthetic
|
Biochemical Assay Reagents
|
Others
|
PTA2 (Pinane thromboxane A2) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
|
-
- HY-U00231
-
-
- HY-N5031
-
|
Others
|
Inflammation/Immunology
|
Mulberrofuran Q inhibits the formation of 12-hydroxy-5,8,10-heptadecatrienoic acid (HHT) and thromboxane B2 (cyclooxygenase products) .
|
-
- HY-19084
-
-
- HY-111271A
-
-
- HY-108564
-
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
L 655240 is thromboxane antagonist. L 655240 attenuates early ischemia- and reperfusion-induced arrhythmias in a canine model of coronary artery occlusion. L 655240 also involves in cancer and autoimmune disorders .
|
-
- HY-B0745
-
-
- HY-100283
-
|
Others
|
Inflammation/Immunology
Endocrinology
|
CGS 15435, a potent thromboxane (TxA2) synthetase inhibitor with an IC50 of 1 nM, has a selectivity for Tx synthetase 100000-fold greater than that for cyclooxygenase, PGI2 synthetase and lipoxygenase enzymes.
|
-
- HY-N2391
-
-
- HY-18763
-
Ibustrin
|
COX
|
Cardiovascular Disease
|
Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes .
|
-
- HY-101236
-
|
Prostaglandin Receptor
|
Endocrinology
|
ICI 192605 is a potent TXA2R (thromboxane A2 receptor) antagonist as cell signaling prostaglandin. ICI 192605 blocks contraction of isolated guinea pig trachea induced by U-46619 .
|
-
- HY-119890
-
-
- HY-121018
-
BM-13505; SKF 96148
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Daltroban (BM-13505) is a selective and specific thromboxane A2 (TXA2) receptor antagonist. Daltroban increase intracellular calcium in vascular smooth muscle cells. Daltroban shows protective effect in reperfusion injury .
|
-
- HY-129199
-
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
U-51605 is a platelet aggregation inhibitor and inhibits thromboxane synthesis. U-51605 is also a prostaglandin I2 synthase inhibitor and can inhibit the retinal vasodilation response induced by NO donors (such as NOR3) .
|
-
- HY-122178
-
|
PGE synthase
|
Cardiovascular Disease
|
5-trans U-44069 is the trans isomer of the thromboxane receptor agonist U-44069 (HY-121825). 5-trans U-44069 inhibits prostaglandin E2 synthase activity .
|
-
- HY-B0745S
-
-
- HY-B1735
-
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Picotamide is a combined inhibitor of thromboxane A2 (TxA2) synthase and receptor. Picotamide has antiplatelet activity. Picotamide promotes the reduction of microalbuminuria and the inhibition of growth of carotid plaques in diabetes. Picotamide can be used for researching acute or chronic cardiovascular diseases .
|
-
- HY-118895
-
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
L-641953 is an orally active, selective TXA/PG-END receptor (thromboxane-prostaglandin endoperoxide receptor) antagonist. L-641953 significantly inhibits arachidonic acid-induced bronchoconstriction. L-641953 may be used in cardiovascular disease research .
|
-
- HY-18763S
-
Ibustrin-d5
|
Isotope-Labeled Compounds
COX
|
Cardiovascular Disease
|
Indobufen-d5 is deuterium labeled Indobufen. Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes[1].
|
-
- HY-18763R
-
|
COX
|
Cardiovascular Disease
|
Indobufen (Standard) is the analytical standard of Indobufen. This product is intended for research and analytical applications. Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes .
|
-
- HY-118736
-
|
Others
|
Cardiovascular Disease
|
Ganodermic acid S is an oxygenated triterpenoid, that can be isolated from the Chinese medicinal fungus Ganoderma lucidum (Fr.) Karst (Polyporaceae). Ganodermic acid S exerts a concentration dependent inhibition on the response of human gel-filtered platelets (GFP) to U-46619 (HY-108566), a thromboxane (TX) A2 mimetic .
|
-
- HY-116431
-
|
Prostaglandin Receptor
|
Cardiovascular Disease
Neurological Disease
|
I-BOP is an agonist for thromboxane A2 receptor (TP) with a KD of 0.61 nM. I-BOP promotes proliferation through activation of PI3K pathway in vascular smooth muscle . I-BOP dose-dependently biphasicly affects the excitatory postsynaptic potential (e.p.s.p.) in hippocampal neurons .
|
-
- HY-13706
-
TM30089 Racemate
|
Prostaglandin Receptor
|
Endocrinology
Cancer
|
CAY10471 Racemate (TM30089 Racemate) is a potent and highly selective prostaglandin D2 receptor CRTH2 antagonist, with a Ki of 0.6 nM for hCRTH2, selective over human thromboxane A2 receptor TP (Ki, >10000 nM) or PGD2 receptor DP (Ki, 1200 nM). CAY10471 Racemate also has effect on mouse and rat orthologs of CRTH2 .
|
-
- HY-B0774
-
-
- HY-U00364
-
-
- HY-108566
-
U-46619
3 Publications Verification
9,11-Methanoepoxy PGH2
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
U-46619 (9,11-Methanoepoxy PGH2) is a stable analogue of Thromboxane A2 (HY-113350) (TXA2) and acts as a potent TXA2 (TP) agonist. U-46619 also is a RhoA agonist. U-46619 stimulates the activation of RhoA through TXA2 receptor activation .
|
-
- HY-105218
-
BMS-180291
|
Prostaglandin Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
Ifetroban (BMS-180291) is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research .
|
-
- HY-105218A
-
BMS-180291 sodium
|
Prostaglandin Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
Ifetroban (BMS-180291) sodium is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban sodium shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban sodium can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research .
|
-
- HY-156329
-
|
Epoxide Hydrolase
FLAP
|
Inflammation/Immunology
|
sEH/FLAP-IN-1 (Compound 46A) is a sEH/FLAP inhibitor. sEH/FLAP-IN-1 inhibits 5-LOX product formation in SACM-stimulated PBMCs (EC50: 11 nM). sEH/FLAP-IN-1 inhibit sEH (EC50: 18 nM) and thromboxane production. sEH/FLAP-IN-1 can be used for research of inflammatory diseases .
|
-
- HY-141469
-
HPA; Heneicosapentaenoic acid methyl ester
|
Others
|
Cardiovascular Disease
Neurological Disease
|
6,9,12,15,18-Heneicosapentaenoic acid (HPA; Heneicosapentaenoic acid methyl ester) inhibits the conversion of α-linoleic acid into Arachidonic acid (HY-109590) in hepatoma cells, the activation of prostaglandin H synthase and thromboxane synthesis in isolated platelets. 6,9,12,15,18-Heneicosapentaenoic acid is weak inducer of acyl-CoA oxidase in hepatoma cells .
|
-
- HY-W612338
-
9-ONA
|
Phospholipase
Prostaglandin Receptor
|
Cardiovascular Disease
|
9-Oxononanoic acid (9-ONA) is secondary reaction product of lipid peroxidation. 9-Oxononanoic acid induces phospholipase A2 (PLA2) activity and thromboxane A2 (HY-113350) production (TXA2). 9-Oxononanoic acid induces the platelet aggregation in human blood. 9-Oxononanoic acid is orally active .
|
-
- HY-125122
-
|
Others
|
Inflammation/Immunology
|
Mulberrofuran A is a natural product, that can be isolated from the root bark of mulberry tree. Mulberrofuran A inhibits the formations of 12-hydroxy-,8,10-heptadecatrienoic acid (HHT) and thromboxane B2 (cyclooxygenase products), but it increases the formation of 12-hydroxy-5,8,10,14-eicosatetraenoic acid (12-HETE) (12-lipoxygenase product) .
|
-
- HY-137227
-
15(R)-Pinanethromboxane A2
|
Others
|
Cardiovascular Disease
|
15(R)-PTA2 (15(R)-Pinanethromboxane A2) is an antithrombotic agent that inhibits platelet aggregation. 15(R)-PTA2 inhibits stable prostaglandin endoperoxide analog-induced constriction of feline coronary arteries and stabilizes hepatic lysosomes. 15(R)-PTA2 also inhibits thromboxane synthase but has no effect on prostacyclin synthase .
|
-
- HY-125626
-
8-iso-15-keto PGF2α
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
8-iso-15-keto Prostaglandin F2α (8-iso-15-keto PGF2α) is a partial agonist for Thromboxane receptor (TP), which exhibits a vasoconstrictor efficacy with a pD2 of 5.8. 8-iso-15-keto Prostaglandin F2α mediates a weak relaxation of rats aorta rings at high concentration .
|
-
- HY-B0774R
-
-
- HY-124428
-
FK881
|
COX
|
Cardiovascular Disease
|
ASP6537 is a potent and selective rhCOX-1 inhibitor with an IC50 of 0.703 nM. ASP6537 has the potential for cardiovascular disease research .
|
-
- HY-137555
-
11-dehydro-2,3-dinor TXB2
|
Others
|
Metabolic Disease
|
11-dehydro-2,3-dinor Thromboxane B2 (11-dehydro-2,3-dinor TXB2) is a metabolite of the TXA2 inactive metabolite TXB2 (Item No. 19030). It is formed from TXB2 by cytosolic aldehyde dehydrogenase (ALDH) and β-oxidation. Levels of 11-dehydro-2,3-dinor TXB2 are increased 5.2-fold in a surgery-induced rat model of tendon overuse.
|
-
- HY-118652
-
ω-3 6-keto PGF2α
|
Others
|
Metabolic Disease
|
Δ17-6-keto Prostaglandin F1α (Δ17-6-keto PGF1α) is a cyclooxygenase (COX) product of eicosapentaenoic acid (EPA) in various tissues such as seminal vesicles, lung, Polymorphonuclear leukocytes, and ocular tissues. Δ17-6-keto PGF1α and other 3-series COX products from EPA, such as PGF3α, PGE3, and thromboxane B3, may be involved in the reduced incidence of glaucoma in patients on a marine-rich (EPA-rich) diet.
|
-
Cat. No. |
Product Name |
Type |
-
- HY-130444
-
Pinane-thromboxanea2synthetic
|
Biochemical Assay Reagents
|
PTA2 (Pinane thromboxane A2) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-113420
-
-
-
- HY-N0652
-
2,3,4',5-Tetrahydroxystilbene 2-O-D-glucoside
|
Structural Classification
Stilbenes
Classification of Application Fields
Polygonaceae
Source classification
Other Diseases
Phenols
Polyphenols
Fallopia multiflora (Thunb.) Harald.
Plants
Disease Research Fields
|
ERK
NF-κB
|
2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside isolats from the roots of Polygonaceae species, inhibits the formation of 5-HETE, HHT and thromboxane B2. 2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside has hypotensive, anti-ageing, anti-inflammatory, hypolipidemic, cardioprotective, and neuroprotective actions .
|
-
-
- HY-120178
-
-
-
- HY-113350
-
-
-
- HY-N5031
-
-
-
- HY-N2391
-
-
-
- HY-118736
-
-
-
- HY-W612338
-
-
-
- HY-125122
-
-
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-113331S
-
|
Thromboxane B2-D4 is the deuterium labeled Thromboxane B2. Thromboxane B2 is a prostaglandin derivative that is released during anaphylaxis. Thromboxane B2 induces arterial contraction and platelet aggregation .
|
-
-
- HY-113420S2
-
|
11-Dehydro-thromboxane B2- 13C5 is 13C labeled 11-Dehydro-thromboxane B2 (HY-113420). 11-Dehydro-thromboxane B2 is a platelet hemagglutinin. Thromboxane inhibition was assessed by urinary excretion levels of 11-Dehydro-thromboxane B2. 11-Dehydro-thromboxane B2 can be used in the study of atherosclerotic thrombosis .
|
-
-
- HY-113420S
-
|
11-Dehydro-thromboxane B2-d4 is the deuterium labeled 11-Dehydro-thromboxane B2[1].
|
-
-
- HY-B0745S
-
|
Ramatroban-d4 is deuterium labeled Ramatroban. Ramatroban is a selective thromboxane A2 (TxA2, IC50=14 nM) antagonist, which also antagonizes CRTH2 (IC50=113 nM) by inhibiting PGD2 binding.
|
-
-
- HY-18763S
-
|
Indobufen-d5 is deuterium labeled Indobufen. Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes[1].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: